Dose-finding of Rivaroxaban in Hemodialysis

Chronic Renal Failure Clinical Trial

Official title: Finding the Optimal Dose of Rivaroxaban in Hemodialysis Patients

Status Completed

Clinical Trial Summary

Rivaroxaban is a recently developed factor Xa (FXa) inhibitor for the prevention and treatment of thromboembolic disease. There are no data on dose adjustments in patients with severe chronic renal failure. It's use is therefore not recommended in this patient population. The present study aims to asses in 12 hemodialysis patients that require prevention of deep vein thrombosis:

1. the AUC and Cmax of 10 mg rivaroxaban

2. the effect of 10 mg rivaroxaban on coagulation assays

3. the effect of a single dialysis session on plasma levels of rivaroxaban and on anti-Xa levels

4. the safety and tolerability of rivaroxaban

Clinical Trial Description

1. Background and Rationale:

Vitamin K antagonists have been the standard anticoagulant treatment for decades, despite their unpredictable pharmacology and their slow onset and offset of action, requiring frequent monitoring and bridging with low molecular weight heparins (LMWH), and resulting in a substantial risk of under- and overtreatment. Patients with end-stage renal disease have an increased risk of bleeding due to their underlying disease. Therefore, anticoagulants need to be used with caution in these patients. In addition, the vitamin K antagonists are increasingly implicated in the development of vascular calcifications in this already vulnerable population. A search for alternative anticoagulants is therefore warranted.

Rivaroxaban is a recently developed factor Xa (FXa) inhibitor for the prevention and treatment of thromboembolic disease (1). Rivaroxaban has a much lower pharmacokinetic variability and little interaction with food and drugs, contributing to consistent and predictable anticoagulation. As a consequence, routine monitoring is not required. Rivaroxaban has been shown to be effective and safe in large trials on the prevention and treatment of venous thromboembolism (2,3) and the prevention of stroke in atrial fibrillation (4).

Rivaroxaban inhibits factor Xa in a concentration-dependent manner. Even though routine monitoring is not required, there are clinical situations in which an evaluation of its anticoagulant effect is desirable. Rivaroxaban prolongs prothrombin time (PT) and activated partial thromboplastin time (aPTTT) in a concentration-dependent manner. However, the extent of prolongation varies considerably with the type of reagent that is used. This variation cannot be reduced by conversion of PT values given in seconds to international normalized ratio values; therefore, PT and activated partial thromboplastin time are not useful for measuring the pharmacodynamic effects of rivaroxaban. Anti- Factor Xa activity is also influenced by rivaroxaban and is the most reliable method to evaluate the clinical effect of rivaroxaban (5).

The absolute bioavailability of rivaroxaban is high (80 % - 100 %) for the 10 mg dose, with maximum plasma concentration (Cmax). appearing 2 - 4 hours after tablet intake. Intake with food does not affect rivaroxaban area under the curve (AUC) or Cmax. Rivaroxaban pharmacokinetics are approximately linear up to about 15 mg once daily. Plasma protein binding in humans is high at approximately 92 % to 95 %, with serum albumin being the main binding component. Due to the high plasma protein binding rivaroxaban is not expected to be dialysable. There are, however, no data about plasma protein binding in hemodialysis patients. Unchanged rivaroxaban is the most important compound in human plasma, with no major or active circulating metabolites being present. With a systemic clearance of about 10 l/h, rivaroxaban can be classified as a low-clearance drug. After intravenous administration of a 1 mg dose the elimination half-life is about 4.5 hours. After oral administration of a 10 mg dose the elimination becomes absorption rate limited with mean terminal half-lives of 7 to 11 hours (6,7).

Rivaroxaban has a dual mode of elimination. Approximately 2/3 of the administered dose is metabolized to inactive metabolites in the liver, with half then being eliminated renally and the other half eliminated by the faecal route. The final 1/3 of the administered dose undergoes direct renal excretion as unchanged active substance in the urine, mainly via active renal secretion (6,7). In individuals with mild (measured creatinine clearance [CreaCl] 50-80 ml/min), moderate (CreaCl 30-49 ml/min) and severe (CreaCl 15-29 ml/min) renal impairment, rivaroxaban plasma concentrations (AUC) were increased 1.4-, 1.5- and 1.6-fold respectively, as compared with control subjects, whereas maximum plasma concentration was relatively unaffected (8). Corresponding increases in pharmacodynamic effects were more pronounced. In individuals with mild, moderate and severe renal impairment the overall inhibition of factor Xa-activity was increased by a factor of 1.5, 1.9 and 2.0 respectively, as compared to healthy volunteers; prolongation of PT was similarly increased by a factor of 1.3, 2.2 and 2.4 respectively (8). There are no data in patients with CreaCl < 15 ml/min. Based on these data, dosing guidelines for patients with renal failure have been issued. No dose adjustment is necessary in patients with mild renal impairment (CreaCl 50-80 ml/min) or moderate renal impairment (CreaCl 30-49 ml/min). In patients with severe renal impairment (CreaCl 15-29 ml/min), rivaroxaban is to be used with caution. Use is not recommended in patients with CreaCl < 15 ml/min (6,7).

2. Study design A two-centre, non-blinded cohort study.

3. Study objectives 1) To measure the AUC and Cmax of 10 mg rivaroxaban in hemodialysis patients 2) To assess the effect of 10 mg rivaroxaban on coagulation assays in hemodialysis patients:

• anti-Xa assay

• prothrombin assay 3) To assess the effect of a single dialysis session on plasma levels of rivaroxaban and on anti-Xa levels 4) To assess safety and tolerability of rivaroxaban in hemodialysis patients

4. Study subjects

1. Enrolment procedure The study protocol will be discussed with eligible patients. All patients under treatment in the participating centers that meet the in- and exclusion criteria that give informed consent will be included.

2. Planned number of participants 12 patients

3. Inclusion criteria

• age ≥18 year

• signed informed consent

• chronic hemodialysis patients without immediate life-threatening conditions, dialysed three times a week for at least three months

• requiring anticoagulation for the prevention of deep venous thrombosis

4. Exclusion criteria

• residual renal function, as defined by a residual diuresis of >50 ml/day

• known intestinal malabsorption

• inability to take oral medication

• mechanical heart valve

• inability to stop co-medication that causes major interactions with rivaroxaban (e.g. ketoconazole, itraconazole, voriconazole, posaconazole, ritonavir)

• severe liver dysfunction Child-Pugh grade C ;

Study Design

Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Chronic Renal Failure
• Kidney Failure, Chronic

• NCT number: NCT02047006
• Study type: Interventional
• Source: AZ Sint-Jan AV
• Status: Completed
• Phase: Phase 4
• Start date: September 2013
• Completion date: October 2014